导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.25% | 896/1840 |
| 近一周 | -2.01% | 1139/2029 |
| 近一月 | -4.47% | 1118/2018 |
| 近一季 | -6.45% | 935/1966 |
| 近半年 | -2.02% | 751/1877 |
| 近一年 | 3.97% | 715/1753 |
| 近两年 | 49.79% | 620/1324 |
| 近三年 | 32.43% | 398/1010 |
| 成立以来 | 38.55% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.05% 3013/4961 |
13.37% 2017/5312 |
- - |
- - |
| 2025 | 22.97% 1922/4813 |
0.25% 1930/3635 |
1.18% 2430/4076 |
20.61% 1950/4524 |
0.51% 1962/4813 |
| 2024 | 16.53% 798/3463 |
2.76% 713/2808 |
-0.77% 833/3014 |
16.66% 1389/3129 |
-2.04% 1936/3463 |
| 2023 | -9.68% 1214/2656 |
4.58% 917/2280 |
-4.49% 1190/2385 |
-2.98% 813/2515 |
-6.80% 1929/2655 |
| 2022 | -20.54% 978/2207 |
-13.17% 709/1919 |
6.19% 756/2016 |
-14.62% 1126/2113 |
0.93% 1427/2208 |
| 2021 | -6.73% 1018/1822 |
-2.15% 590/1255 |
1.05% 1070/1330 |
-7.04% 1016/1466 |
1.48% 911/1822 |
| 2020 | 33.06% 466/1250 |
-10.09% 753/1028 |
12.04% 702/1067 |
14.72% 262/1164 |
15.15% 231/1184 |
| 2019 | - - |
- - |
- - |
0.25% 542/850 |
5.68% 690/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证A100ETF联接C VS. 长安沪深300非周期A(740101) |